Semaglutide is a GLP-1 receptor agonist FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 with a weight-related condition. Brentwood is among Tennessee's most affluent communities, home to healthcare executives, music-industry leaders and corporate professionals for whom time and discretion are non-negotiable. Telehealth delivers care on those terms: a licensed Tennessee physician reviews your online assessment under Tennessee Telemedicine Practice Act (T.C.A. §63-1-155), and compounded semaglutide from an FDA-registered 503B pharmacy ships discreetly to your Williamson home. Monthly cost runs $199–$379 versus about $1,247 for brand-name Ozempic or Wegovy. Medical Director: Dr. Katherine Moore, MD, Board-Certified Internal Medicine.
Across Williamson, part of the greater Brentwood, TN metro — from John Frost House, Mooreland Brentwood Tennessee and Battle of Brentwood — a growing number of residents are turning to licensed telehealth for Semaglutide and tirzepatide weight loss, prescribed online and shipped straight to the door.
Yes. Under Tennessee Telemedicine Practice Act (T.C.A. §63-1-155), a Tennessee-licensed physician may prescribe weight-management medications including semaglutide via video or reviewed questionnaire. The Tennessee Board of Medical Examiners oversees these providers at tn.gov/health/health-program-areas/health-regulation/boards/meb. No prior in-person visit is required - ideal for Williamson professionals who value privacy and time.
Yes. Williamson residents can complete an online assessment and, if appropriate, receive a Semaglutide prescription within 24 to 48 hours without a clinic visit. The prescriber must be licensed in Tennessee and follow Tennessee Telemedicine Practice Act (T.C.A. §63-1-155) - discreet care that fits a leadership calendar.
The Tennessee Board of Medical Examiners (tn.gov/health/health-program-areas/health-regulation/boards/meb) requires telehealth clinicians serving Williamson to maintain Tennessee licensure, document each encounter and obtain informed consent. Compounded Semaglutide must come from an FDA-registered 503B facility - exacting standards that match the expectations of a discerning patient.
No. Tennessee Telemedicine Practice Act (T.C.A. §63-1-155) permits prescribing without a prior face-to-face relationship for patients across Williamson and Tennessee. A video consult or reviewed questionnaire meets the standard of care under Tennessee Board of Medical Examiners rules, so treatment can begin privately from home.
Yes. Licensed providers serving Williamson must comply with HIPAA: encrypted records, agreements with pharmacy partners, and strict access controls. For executives who guard their privacy, health information is handled with the confidentiality you expect.
Brand-name GLP-1 drugs average about $1,247/month at Williamson pharmacies. Compounded semaglutide via telehealth, made under 503B standards, typically runs $199–$379/month including the prescription - and even at the highest tier, it spares the time a clinic visit would cost.
Coverage varies. Many plans require prior authorization or exclude weight-loss drugs, and Medicare excludes Wegovy. For Williamson professionals who prefer not to involve insurance, paying cash for compounded semaglutide at $199–$379/month is simpler, faster and more private.
Brentwood professionals frequently choose cash-pay compounded semaglutide through telehealth - for privacy and speed as much as price. At $199–$379/month against roughly $1,247/month retail for branded versions, it keeps treatment off the insurance record and on your timeline.
In-person clinics serving Williamson generally charge 150 to 300 dollars per visit plus medication. A telehealth program at $199–$379/month cuts travel and per-visit cost, with compounded Semaglutide shipped discreetly from a 503B pharmacy to your door.
Semaglutide copies GLP-1, a hormone the gut releases after eating. It prompts insulin when glucose is high, lowers glucagon, slows stomach emptying so fullness lasts, and reduces appetite signals in the brain. The result is steady weight loss - a clinical edge against the dinners, travel and stress of executive life.
Semaglutide (Ozempic, Wegovy) is a single-pathway GLP-1 agonist approved for weight management in 2021. Tirzepatide (Mounjaro, Zepbound) also activates GIP and produced greater average loss - about 22.5 percent in SURMOUNT-1 versus 14.9 percent for semaglutide in STEP-1. Both are available to Williamson patients by telehealth.
The branded products hold FDA approval: Wegovy (semaglutide 2.4 mg weekly) since June 2021 for a BMI of 30 or higher, or 27 with a related condition, and Ozempic for type 2 diabetes. Compounded semaglutide is prepared under Section 503B of the FD&C Act by registered facilities.
In STEP-1 (NEJM, 2021), adults on semaglutide 2.4 mg weekly lost an average of 14.9 percent of body weight over 68 weeks versus 2.4 percent on placebo. STEP-4 showed stopping led to regain - which is why Williamson clinicians frame it as sustained, managed treatment rather than a brief course.
Under FDA labeling, treatment suits adults with a BMI of 30 or higher, or 27 or higher when accompanied by a condition like hypertension, type 2 diabetes or dyslipidemia. Telehealth clinicians serving Williamson apply these same thresholds, verified through your assessment and reported history.
Most providers serving Williamson require a BMI of 27 or higher with a related condition, or 30 or higher on its own. Self-reported measurements are accepted for screening; the reviewing physician may request confirmation before prescribing.
The side effects seen most often in trials - nausea, vomiting, diarrhea, constipation and abdominal discomfort - tend to surface during dose escalation and settle as the body adapts. Serious problems like pancreatitis or gallbladder disease are rare. Your prescriber reviews all contraindications, including any family or personal history of medullary thyroid cancer, beforehand.
Typical pre-treatment labs include a metabolic panel, complete blood count, HbA1c, lipid panel and TSH. Many providers accept recent results from your primary care physician or concierge practice. Williamson patients can complete any missing work at nearby Quest or LabCorp draw sites.
Two-year continuous-use findings from the SUSTAIN and STEP extension programs point to a stable safety profile. The 2023 SELECT trial additionally recorded a 20 percent reduction in major cardiovascular events in adults with overweight or obesity and heart disease - support for treatment that continues beyond initial weight loss.
Yes. Semaglutide, marketed as Ozempic, is FDA-approved for blood-sugar management in type 2 diabetes and is routinely prescribed by telehealth clinicians serving Williamson. For patients with both diabetes and obesity it addresses each. Disclose all current medications in your assessment so the physician can check for interactions.
Four steps: a 10 to 15 minute online assessment; review by a licensed Tennessee physician within 24 hours; prescription to a 503B pharmacy if approved; medication shipped discreetly to your Williamson address. No in-person visit is required under Tennessee Telemedicine Practice Act (T.C.A. §63-1-155) - concierge-style care without the clinic.
Most Williamson patients get a prescription within 24 to 48 hours of completing the assessment, with overnight temperature-controlled shipping after approval. Deliveries to Williamson ZIP codes 37027, 37067 typically arrive within one to two business days, discreetly packaged.
Your visit reviews the health assessment, your history and medications, BMI and related conditions, and the semaglutide dosing plan, ending in a prescription when appropriate. Dr. Katherine Moore, MD, Board-Certified Internal Medicine, oversees clinical review for Williamson patients - thorough, personal attention without the commute.
Semaglutide for weight management is a once-weekly subcutaneous injection from a pre-filled pen. You start at 0.25 mg weekly for four weeks and step up over 16 to 20 weeks to a 2.4 mg maintenance dose. Discreet instructions ship with your first order, and the care team guides you through the first injection.
Keep unopened pens refrigerated at 36 to 46 F. After first use a pen can stay at room temperature up to 77 F for 28 days. Don't freeze or leave it in direct sun, and refrigerate Tennessee summer deliveries promptly - your concierge or household staff can help if you travel.
Tennessee has an uninsured rate of 9.8%, and even well-insured Williamson professionals face plan exclusions for weight-loss drugs. For those who prefer to pay privately, a cash-pay telehealth semaglutide program at $199–$379/month is a discreet alternative to clinic-based care.
In Williamson the appeal is privacy and white-glove convenience: no clinic where you might be recognized, no waiting room, care delivered to the door, predictable $199–$379/month pricing, and no prior-auth delay. For executives accustomed to concierge service, weight-loss care that comes to them - discreetly - is the obvious standard.
A GLP-1 receptor agonist is a lab-made medicine that reproduces glucagon-like peptide-1, the gut hormone released after meals to regulate hunger and blood sugar. Developed first for type 2 diabetes, it is now used at higher doses for weight management. Telehealth has broadened access to this class for Williamson residents since 2022.
Semaglutide is the molecule; Ozempic and Wegovy are Novo Nordisk's brand names for it - Ozempic at diabetes dosing (0.5 to 2 mg weekly), Wegovy at weight-loss dosing (2.4 mg weekly). Through licensed TN telehealth, compounded semaglutide offers the same active ingredient at a lower cost.
Although the compounded form of semaglutide is not FDA-approved, FDA-registered 503B outsourcing facilities are legally authorized to prepare it under Section 503B of the FD&C Act. Federal shortage-related guidance followed in 2024 and 2025. A TN-licensed physician may prescribe it to Williamson patients when clinically appropriate.
The standard ramp is 0.25 mg weekly for four weeks, then 0.5, 1.0, 1.7 and finally 2.4 mg weekly, about four weeks per step. Williamson patients with stronger GI effects can titrate more slowly - a measured build that keeps a demanding travel and meeting schedule undisturbed.
On semaglutide 2.4 mg weekly, STEP-1 participants shed an average of 14.9 percent of body weight across 68 weeks. Among Williamson patients who complete the full titration, real-world outcomes commonly range from 8 to 20 percent, influenced by adherence, diet and baseline weight.
All clinical content here is reviewed by Dr. Katherine Moore, MD, Board-Certified Internal Medicine, licensed in Tennessee. Prescriptions issue only after a licensed Tennessee physician reviews your assessment. The program follows Tennessee Telemedicine Practice Act (T.C.A. §63-1-155) and Tennessee Board of Medical Examiners standards - the rigor and discretion Williamson professionals expect, delivered online.
GLP-1 Telehealth Brentwood connects Williamson residents with licensed physicians for FDA-regulated GLP-1 therapy, with a concierge-grade, discreet experience for executives and professionals. Our team specializes in metabolic and weight-management telehealth. Medical Director: Dr. Katherine Moore, MD, Board-Certified Internal Medicine. We serve patients across Williamson and the greater Nashville area.
Medical Director: Dr. Katherine Moore, MD, Board-Certified Internal Medicine. Licensed in Tennessee. All prescriptions issued under Tennessee Telemedicine Practice Act (T.C.A. §63-1-155) and supervised by Tennessee Board of Medical Examiners.